CN1477956A - 用于预防和延缓早期老年痴呆症的隐丹参酮 - Google Patents
用于预防和延缓早期老年痴呆症的隐丹参酮 Download PDFInfo
- Publication number
- CN1477956A CN1477956A CNA018197590A CN01819759A CN1477956A CN 1477956 A CN1477956 A CN 1477956A CN A018197590 A CNA018197590 A CN A018197590A CN 01819759 A CN01819759 A CN 01819759A CN 1477956 A CN1477956 A CN 1477956A
- Authority
- CN
- China
- Prior art keywords
- cryptotanshinone
- ammonia
- senile dementia
- brain
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 19
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 15
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims abstract description 79
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 123
- 229910021529 ammonia Inorganic materials 0.000 claims description 61
- 210000005013 brain tissue Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 15
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 8
- 241000700159 Rattus Species 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 19
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical class C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 206010020575 Hyperammonaemia Diseases 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 240000007164 Salvia officinalis Species 0.000 description 9
- 230000003188 neurobehavioral effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000005412 red sage Nutrition 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 229930183118 Tanshinone Natural products 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 238000011552 rat model Methods 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013923 monosodium glutamate Nutrition 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229940073490 sodium glutamate Drugs 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical group OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- -1 patch Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- PBXYLMVLLSYZLN-UHFFFAOYSA-N 5beta-Ranol Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)CCO)C)C1(C)C(O)C2 PBXYLMVLLSYZLN-UHFFFAOYSA-N 0.000 description 1
- 102000006267 AMP Deaminase Human genes 0.000 description 1
- 108700016228 AMP deaminases Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 权利要求1 . 式 (I) 所示结构的隐丹参酮或含有该隐丹参酮的药学组合物 在制造预防和延缓早期老年痴呆症药物中的用途:( I )。2. 根据权利要求 1所述的用途, 式 ( 1 ) 所示的隐丹参酮能够 通过血脑屏障进入到脑组织中, 通过清除早期老年痴呆症病人脑组织 中不正常高浓度氨, 达到预防和延缓早期老年痴呆症的目的。3. 一种用于预防和延缓早期老年痴呆症的药物, 其中含有权利要 求 1的式 ( I ) 所示的隐丹参酮, 以及任意的药学上可接受的稀释剂 或载体。4. 一种制备用于预防和延缓老年痴呆症的药学组合物的方法, 其 中包括将权利要求 1的式(1 )所示结构的隐丹参酮与任意的药学上可 接受的稀释剂或载体一起配制。5. —种用于预防和延缓早期老年痴呆症的方法, 其中包括使用有 效量的根据权利要求 1所示的隐丹参酮或其药学组合物对患者进行治 疗。6. 根据权利要求 1或 2所述的用途, 其中所述药物是以注射剂、 片剂、 丸剂、 胶囊剂、 溶液、 悬浮剂、 乳剂的形式使用。7. 根据权利要求 1或 2所述的用途, 其中所述药物的给药途径包 括口服、 经皮、 静脉、 肌肉、 皮下或直肠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB018197590A CN1210024C (zh) | 2001-01-16 | 2001-10-23 | 用于预防和延缓早期老年痴呆症的隐丹参酮 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN01107460.4 | 2001-01-16 | ||
CN01107460A CN1304723A (zh) | 2001-01-16 | 2001-01-16 | 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物 |
CNB018197590A CN1210024C (zh) | 2001-01-16 | 2001-10-23 | 用于预防和延缓早期老年痴呆症的隐丹参酮 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1477956A true CN1477956A (zh) | 2004-02-25 |
CN1210024C CN1210024C (zh) | 2005-07-13 |
Family
ID=4656388
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01107460A Pending CN1304723A (zh) | 2001-01-16 | 2001-01-16 | 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物 |
CNB018197604A Expired - Fee Related CN1210025C (zh) | 2001-01-16 | 2001-05-24 | 用于治疗高血氨症及肝性脑病的含二氢呋喃环结构的丹参酮类化合物 |
CNB018197590A Expired - Fee Related CN1210024C (zh) | 2001-01-16 | 2001-10-23 | 用于预防和延缓早期老年痴呆症的隐丹参酮 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01107460A Pending CN1304723A (zh) | 2001-01-16 | 2001-01-16 | 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物 |
CNB018197604A Expired - Fee Related CN1210025C (zh) | 2001-01-16 | 2001-05-24 | 用于治疗高血氨症及肝性脑病的含二氢呋喃环结构的丹参酮类化合物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20040024056A1 (zh) |
EP (2) | EP1352653A1 (zh) |
JP (2) | JP2004517134A (zh) |
CN (3) | CN1304723A (zh) |
WO (2) | WO2002055070A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108478547A (zh) * | 2018-04-10 | 2018-09-04 | 成都大学 | 一种用于治疗阿尔兹海默症的药物及其制备方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040191334A1 (en) * | 2003-03-24 | 2004-09-30 | Pang-Chui Shaw | Use of transhinone derivates as cholinesterase inhibitors in treating related diseases |
KR100687247B1 (ko) | 2005-06-15 | 2007-02-26 | 원광대학교산학협력단 | 크립토탄시논을 함유하는 간질환 치료 및 예방을 위한조성물 |
KR100725839B1 (ko) * | 2005-10-06 | 2007-12-11 | 일성신약주식회사 | 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물 |
WO2007084419A2 (en) * | 2006-01-13 | 2007-07-26 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production with tanshinones |
KR100734513B1 (ko) | 2006-11-02 | 2007-07-03 | 원광대학교산학협력단 | 크립토탄시논을 함유하는 간질환 치료 및 예방을 위한조성물 |
KR100734512B1 (ko) | 2006-11-02 | 2007-07-03 | 원광대학교산학협력단 | 탄시논ⅰ을 함유하는 간질환 치료 및 예방을 위한 조성물 |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
BRPI1012956A8 (pt) | 2009-06-08 | 2021-11-03 | Ocera Therapeutics Inc | Usos da l-ornitina e de pelo menos um de fenilacetato e fenilbutirato |
KR101400900B1 (ko) * | 2012-01-26 | 2014-05-29 | 한국생명공학연구원 | 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물 |
WO2014138357A1 (en) * | 2013-03-06 | 2014-09-12 | The University Of Akron | Novel tashinone drugs for alzheimer disease |
CN107206021B (zh) | 2014-11-24 | 2021-09-03 | Ucl商业有限公司 | 使用降氨疗法治疗与肝星状细胞激活相关的疾病 |
WO2017053613A1 (en) * | 2015-09-25 | 2017-03-30 | Ocera Therapeutics, Inc. | Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
CN115666576A (zh) | 2020-05-15 | 2023-01-31 | 上海科技大学 | 一种治疗和/或预防冠状病毒引发的疾病的化合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
IT1274481B (it) * | 1995-05-12 | 1997-07-17 | Indena Spa | Composizioni farmaceutiche per il trattamento della alcol-dipendenza |
CN1277840A (zh) * | 2000-07-11 | 2000-12-27 | 上海维来现代科技发展有限公司 | 丹参酮固体分散物及其制备方法 |
AU2001286409A1 (en) * | 2000-08-03 | 2002-02-18 | Hong Kong University Of Science And Technology | N-methyl-d-aspartate receptor antagonists |
CN1286083A (zh) * | 2000-08-08 | 2001-03-07 | 上海维来现代科技发展有限公司 | 丹参酮微粉制剂及其微波辅助共研磨制备方法 |
-
2001
- 2001-01-16 CN CN01107460A patent/CN1304723A/zh active Pending
- 2001-05-24 WO PCT/CN2001/000861 patent/WO2002055070A1/zh not_active Application Discontinuation
- 2001-05-24 CN CNB018197604A patent/CN1210025C/zh not_active Expired - Fee Related
- 2001-05-24 JP JP2002555804A patent/JP2004517134A/ja active Pending
- 2001-05-24 US US10/399,468 patent/US20040024056A1/en not_active Abandoned
- 2001-05-24 EP EP01940097A patent/EP1352653A1/en not_active Withdrawn
- 2001-10-23 WO PCT/CN2001/001497 patent/WO2002060435A1/zh not_active Application Discontinuation
- 2001-10-23 US US10/399,957 patent/US20040039050A1/en not_active Abandoned
- 2001-10-23 CN CNB018197590A patent/CN1210024C/zh not_active Expired - Fee Related
- 2001-10-23 EP EP01273578A patent/EP1364648A4/en not_active Withdrawn
- 2001-10-23 JP JP2002560627A patent/JP4377130B2/ja not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108478547A (zh) * | 2018-04-10 | 2018-09-04 | 成都大学 | 一种用于治疗阿尔兹海默症的药物及其制备方法 |
CN108478547B (zh) * | 2018-04-10 | 2019-12-17 | 成都大学 | 一种用于治疗阿尔兹海默症的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2002060435A1 (fr) | 2002-08-08 |
JP4377130B2 (ja) | 2009-12-02 |
US20040039050A1 (en) | 2004-02-26 |
WO2002055070A1 (fr) | 2002-07-18 |
CN1477957A (zh) | 2004-02-25 |
EP1364648A1 (en) | 2003-11-26 |
JP2004517134A (ja) | 2004-06-10 |
EP1364648A4 (en) | 2004-10-13 |
WO2002060435A8 (fr) | 2004-05-21 |
CN1210024C (zh) | 2005-07-13 |
JP2004517939A (ja) | 2004-06-17 |
EP1352653A1 (en) | 2003-10-15 |
CN1304723A (zh) | 2001-07-25 |
CN1210025C (zh) | 2005-07-13 |
US20040024056A1 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106102737B (zh) | 色甘酸衍生物以及成像和治疗的相关方法 | |
CN1477956A (zh) | 用于预防和延缓早期老年痴呆症的隐丹参酮 | |
US6605305B2 (en) | Plant drug for treatment of liver disease | |
US6051613A (en) | Nitrogen monoxide production suppressor | |
AU2017366514A1 (en) | Piperidine-2,6-dione derivative and treatment for ulcerative colitis | |
Tyce et al. | 5-Hydroxyindole metabolism in the brain after hepatectomy | |
BRPI0814725B1 (pt) | Uso da composição antiviral | |
TWI472335B (zh) | 用以治療腸激躁症之山薑屬植物萃取物 | |
CN105641004A (zh) | 一种由银杏叶提取物形成的中药组合物及其在制备舒血宁注射液中的应用 | |
BRPI0706865A2 (pt) | método para preparar extrato de shinyleaf yellowhorn e extrato de shinyleaf yellowhorn | |
CN1278433A (zh) | 一种溶栓药物,其制备方法及其用途 | |
BRPI0617264A2 (pt) | composição farmacêutica útil como agente leishmanicidal | |
KR20170003293A (ko) | 모과 추출물을 포함하는 뇌신경질환 예방 또는 치료용 의약 조성물 | |
BRPI0804764A2 (pt) | inibidores da alfa-glicosidades, composições farmacêuticas compreendendo os mesmos e processo para sua preparação | |
PL212111B1 (pl) | Sposób prowadzenia reakcji alkaloidów, produkt reakcji alkaloidów i zastosowanie produktu reakcji alkaloidów | |
KR0150823B1 (ko) | 해열진통제 조성물 | |
JPH0212932B2 (zh) | ||
JPS6245526A (ja) | ストレスによる機能障害改善剤 | |
BR102018073535B1 (pt) | Processo de obtenção do composto palmitato de fisetinidol e seu uso como agente analgésico e antirreabsortivo | |
JP2022168636A (ja) | ヤヌスキナーゼ阻害剤 | |
JPH10175860A (ja) | 津液改善剤及びそれを含有する経口投与用組成物 | |
JPH0912451A (ja) | 抗ヘリコバクター・ピロリ薬 | |
CN117018095A (zh) | 一种治疗孤独症的药物组合物及其应用 | |
BR102018073535A2 (pt) | Processo de obtenção do composto palmitato de fisetinidol e seu uso como agente analgésico e antirreabsortivo | |
CN1994336A (zh) | 贯众总多糖在制备防治急性呼吸窘迫综合征药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIBET LIJIAN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHONGSHAN UNIVERSITY Effective date: 20141020 Free format text: FORMER OWNER: GUANGZHOU MAITE ZHONGDA BIOTECHNOLOGY CO., LTD. Effective date: 20141020 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510000 GUANGZHOU, GUANGDONG PROVINCE TO: 850000 LHASA, TIBET AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141020 Address after: Kim Lhasa City West Tibet autonomous region 850000 No. 158 Metro sunshine B District three unit two building No. 4-1 Patentee after: Tibet Kin Kin biological Polytron Technologies Inc. Address before: 510000 Xingang West Road, Guangdong, China, No. 135, No. Patentee before: Sun Yat-sen University Effective date of registration: 20141020 Address after: 510000 Xingang West Road, Guangdong, China, No. 135, No. Patentee after: SUN YAT-SEN University Address before: 510000 Xingang West Road, Guangdong, China, No. 135, No. Patentee before: Sun Yat-sen University Patentee before: Guangzhou Mater Zhongda Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190131 Address after: Room 1702, No. 1, Jinsui Road, Tianhe District, Guangzhou City, Guangdong 510000 Patentee after: Guangzhou Meiqi Biotechnology Co.,Ltd. Address before: No. 4-1, No. 158 Jinzhu West Road, Three Two Units, Sunshine New Town B District, Lhasa City, Tibet Autonomous Region Patentee before: Tibet Kin Kin biological Polytron Technologies Inc. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050713 Termination date: 20201023 |
|
CF01 | Termination of patent right due to non-payment of annual fee |